2022 Memorial Sloan Kettering Cancer Center Academic Convocation and Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences Commencement

Levi Garraway, MD, PhD, is Chief Medical Officer and Executive Vice President for Roche and Genentech, where he leads product development, oversees all aspects of late-stage clinical development, and co-chairs the late-stage portfolio committee. He is also a member of Genentech’s Board of Directors. Prior to joining Genentech and Roche, Dr. Garraway served as Senior Vice President, Oncology Research and Development and Novel Target Research, at Eli Lilly and Company. Before that, he was a Howard Hughes Medical Institute Investigator, an associate professor of medicine at the Dana-Farber Cancer Institute (DFCI) and Harvard Medical School, and an Institute Member of the Broad Institute, where he led a research group that studied cancer genomics and drug resistance and developed a platform for systematic cancer mutation profiling. While in Boston, he also served as the inaugural director of the Joint Center for Cancer Precision Medicine. Dr. Garraway is an elected member of the American Society for Clinical Investigation, the American Association for Cancer Research Academy, and the National Academy of Medicine and has received numerous awards, including the Paul Marks Prize for Cancer Research from Memorial Sloan Kettering Cancer Center (MSK). He serves on several advisory boards and committees, including the Board of Scientific Consultants at MSK. He received AB, MD, and PhD degrees from Harvard; completed postdoctoral training in internal medicine at the Massachusetts General Hospital; and trained as a fellow in medical oncology at DFCI.